Flavones, a subclass of flavonoids found in many fruits, vegetables, and medicinal plants, have been investigated for their potential effects on depression. Preclinical studies provide some scientific basis for their use: animal models have shown that certain flavones, such as apigenin and luteolin, may produce antidepressant-like effects. Mechanisms proposed include modulation of monoaminergic neurotransmission (serotonin, dopamine, norepinephrine), inhibition of neuroinflammation, and antioxidant effects. For example, apigenin has been shown to increase brain-derived neurotrophic factor (BDNF) expression and reduce depressive-like behavior in rodents.

However, there is limited direct clinical evidence in humans. Most studies are either in vitro or involve animal models; only a few small human trials have looked at broader flavonoid-rich diets or extracts, often with mixed or modest results. No large-scale randomized controlled trials have specifically established the efficacy of isolated flavones for depression in humans.

In summary, while there is some scientific rationale and preliminary evidence from animal studies for the antidepressant potential of flavones, clinical validation is lacking, and evidence in humans remains insufficient. Thus, the evidence rating is low, but not absent, reflecting early-stage scientific interest rather than established clinical use.